131 related articles for article (PubMed ID: 28384599)
1. The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine.
Ghazi Suliman MA; Ogungbenro K; Kosmidis C; Ashworth A; Barker J; Szabo-Barnes A; Davies A; Feddy L; Fedor I; Hayes T; Stirling S; Malagon I
J Crit Care; 2017 Aug; 40():113-118. PubMed ID: 28384599
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a rapid ultra high performance liquid chromatography with tandem mass spectrometry method for the simultaneous determination of darunavir, ritonavir, and tenofovir in human plasma: Application to human pharmacokinetics.
Reddy AV; Jaafar J; Aris AB; Majid ZA; Umar K; Talib J; Madhavi G
J Sep Sci; 2015 Aug; 38(15):2580-7. PubMed ID: 25989063
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
5. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Blackman AL; Heil EL; Devanathan AS; Pandit NS
Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.
Colbers A; Greupink R; Litjens C; Burger D; Russel FG
Clin Pharmacokinet; 2016 Mar; 55(3):381-96. PubMed ID: 26369773
[TBL] [Abstract][Full Text] [Related]
7. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
8. Darunavir concentration in PBMCs may be a better indicator of drug exposure in HIV patients.
Nagano D; Araki T; Yanagisawa K; Ogawa Y; Gohda F; Uchiumi H; Handa H; Nakamura T; Yamamoto K
Eur J Clin Pharmacol; 2018 Aug; 74(8):1055-1060. PubMed ID: 29721582
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
[TBL] [Abstract][Full Text] [Related]
10. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
Di Yacovo MS; Moltó J; Ferrer E; Curran A; Else L; Gisslén M; Clotet B; Tiraboschi JM; Niubò J; Vila A; Zetterberg H; Back D; Podzamczer D
J Antimicrob Chemother; 2015 May; 70(5):1513-6. PubMed ID: 25608583
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
Flynn P; Komar S; Blanche S; Giaquinto C; Noguera-Julian A; Welch S; Lathouwers E; Van de Casteele T; Kakuda TN; Opsomer M
Pediatr Infect Dis J; 2014 Sep; 33(9):940-5. PubMed ID: 25361024
[TBL] [Abstract][Full Text] [Related]
12. Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.
Curran A; Martí R; López RM; Pérez M; Crespo M; Melià MJ; Navarro J; Burgos J; Falcó V; Ocaña I; Ribera E
Antimicrob Agents Chemother; 2015 Nov; 59(11):6782-90. PubMed ID: 26282411
[TBL] [Abstract][Full Text] [Related]
13. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
McConnachie LA; Kinman LM; Koehn J; Kraft JC; Lane S; Lee W; Collier AC; Ho RJY
J Pharm Sci; 2018 Jul; 107(7):1787-1790. PubMed ID: 29548975
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
[TBL] [Abstract][Full Text] [Related]
15. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
[TBL] [Abstract][Full Text] [Related]
16. Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.
Madelain V; Le MP; Champenois K; Charpentier C; Landman R; Joly V; Yeni P; Descamps D; Yazdanpanah Y; Peytavin G
J Antimicrob Chemother; 2017 Apr; 72(4):1137-1146. PubMed ID: 28065890
[TBL] [Abstract][Full Text] [Related]
17. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.
Calcagno A; Yilmaz A; Cusato J; Simiele M; Bertucci R; Siccardi M; Marinaro L; D'Avolio A; Di Perri G; Bonora S
AIDS; 2012 Jul; 26(12):1529-33. PubMed ID: 22555164
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
[TBL] [Abstract][Full Text] [Related]
19. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
Elliot ER; Amara A; Pagani N; Else L; Moyle G; Schoolmeesters A; Higgs C; Khoo S; Boffito M
J Antimicrob Chemother; 2017 Jul; 72(7):2035-2041. PubMed ID: 28407075
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]